Michael A. Mussallem was appointed chairman and chief executive officer of Edwards Lifesciences in 2000, when it became an independent, publicly traded company. Under his leadership, Edwards has established its position as a global leader in patient-focused medical innovations with the introduction of lifesaving and life-sustaining therapies such as transcatheter aortic valve replacement, rapid-deployment surgical heart valve replacement and non-invasive hemodynamic monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives while delivering value to the healthcare system. Mussallem has not only led the development and successful implementation of the company’s patient-focused innovation strategy, but also established Edwards’ commitment to philanthropy and corporate social responsibility. Over the last 13 years, Edwards Lifesciences Foundation has supported communities and causes around the world with more than $60 million in charitable giving and volunteerism. In 2014, Edwards Lifesciences Foundation launched Every Heartbeat Matters with the goal to reach 1 million underserved people by 2020. In 2019, the foundation exceeded that goal and has since increased the commitment to reach 1.5 million patients by 2020. During Mussallem’s tenure, Edwards was recognized among the World’s Most Ethical Companies by the Ethisphere Institute, an organization that defines and advances standards of ethical business practices. In 2018, Edwards Lifesciences was named as one of the Management Top 250 by the Wall Street Journal in partnership with the Drucker Institute, and was also cited as one of the “7 Companies That Do Everything Well” achieving high marks in five dimensions of corporate performance. Mussallem has been included in the Forum for Corporate Directors Hall of Fame and received a number of honors including the UC Irvine Medal, a lifetime achievement award from The Phoenix Conference and the Wenger Award for Excellence in Corporate Leadership by WomenHeart. Prior to his current position, Mussallem held a variety of positions at Baxter International from 1979 until 2000, when Edwards was spun off from Baxter. Currently, Mussallem serves on the board of the Advanced Medical Technology Association (AdvaMed) and is an advisory board member for the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California. He is a trustee of the University of California, Irvine Foundation and the Rose-Hulman Institute of Technology in Terre Haute, Indiana. Mussallem has served as board chairman of both AdvaMed and the California Healthcare Institute (CHI). He received a bachelor's degree in chemical engineering and an honorary doctorate degree from the Rose-Hulman Institute of Technology.

Donald E. Bobo, Jr., has been corporate vice president since 2007 and is currently responsible for the company’s corporate strategy and corporate development functions. In addition, Bobo has executive responsibility for disease awareness and heart failure initiatives as well as the healthcare solutions and commercial services team. Bobo has more than 30 years of experience in the medical products and healthcare industry in various leadership roles at Edwards including, most recently, the development of the company’s Transcatheter Mitral and Tricuspid Therapies organization, vice president and general manager of the Surgical Structural Heart business and global valve manufacturing operations. Prior to joining Edwards, Bobo held a variety of roles with increasing levels of responsibilities with American Hospital Supply and Baxter Healthcare, including research and development, business development, operations and general management. He has served as board chairman of the California Life Sciences Association (CLSA). Bobo received a bachelor's degree in mathematics from Bob Jones University, and a master's degree in engineering from the University of Southern California.

Todd J. Brinton, M.D., joined Edwards as corporate vice president, advanced technology and chief scientific officer in February 2019. Dr. Brinton has significant experience as a champion of cardiovascular innovation, as well as a strong patient focus as a practicing clinician. He has deep ties to the medical technology community as a co-founder, board member and advisor to a number of start-up companies. Dr. Brinton began his career as an engineer in the medical technology industry, ultimately becoming a director of clinical research and development, prior to enrolling in medical school. Before joining Edwards, he was clinical professor of medicine (cardiology) and adjunct professor of bioengineering at the Stanford University School of Medicine. He has been an attending interventional cardiologist at both the Stanford University Medical Center and the Palo Alto VA Medical Center. He has served as the fellowship director at the Stanford Byers Center for Biodesign since 2006 where he has worked with numerous teams on the development of new technologies. In addition, he serves as the co-director for both the graduate and executive education programs at the center. Dr. Brinton received his bachelor’s degree from the University of California, San Diego in biomedical engineering. He earned his medical degree from the Chicago Medical School, and completed his internship, residency, and fellowships in both cardiology and interventional cardiology at Stanford.

Daveen Chopra joined Edwards as corporate vice president, Surgical Structural Heart in June 2018. Chopra has broad experience in the medical technology industry including global leadership in strategy, marketing, commercial operations, research and development, and program management. Prior to joining Edwards, Chopra held various roles with increasing levels of responsibility at Medtronic. He was the global leader, serving as vice president and general manager, of Medtronic’s aortic franchise, part of Medtronic’s aortic and peripheral vascular business. Chopra previously served as vice president of global marketing leading Medtronic’s endovascular therapies business. While in Medtronic’s endovascular therapies business, he served as vice president, U.S. commercial operations, director of program management office, senior business manager for the endovascular and peripheral business in Asia-Pacific, global group product manager for thoracic stent grafts, and international aortic product manager. Prior to Medtronic, Chopra served as an international strategy consultant at The Parthenon Group supporting clients in various industries ranging from education to industrial manufacturing. Chopra earned a dual bachelors degree in economics and biology from Duke University, and a masters from Harvard Business School, where he graduated with honors.

Dirksen J. Lehman has been corporate vice president, public affairs, since June 2013. He joined the company in 2007 as vice president of government affairs, and later added responsibility for global health economics and reimbursement. In his current role, Lehman continues to oversee these functions and also has responsibility for global communications, corporate branding, global corporate giving, and patient engagement. Prior to joining Edwards, he was head of the healthcare practice at Clark & Weinstock, a government affairs and crisis management consulting firm in Washington, D.C. Lehman has also served in The White House as special assistant to the president for legislative affairs, and health counsel for the majority on the U.S. Senate Committee on Health, Education, Labor and Pensions. He serves on the board of directors for California Life Sciences Association. Lehman received his undergraduate degree from Millersville University of Pennsylvania and his law degree from Catholic University of America.

Jean-Luc Lemercier has been corporate vice president, EMEA (Europe, Middle East and Africa), Canada and Latin America since July 2017. Prior to assuming his current role, Lemercier served as vice president of transcatheter heart valves EMEA since 2008. Under his leadership at Edwards, the company successfully launched the SAPIEN transcatheter heart valve technology and built its leadership position in Europe. Before joining Edwards, Lemercier served various leadership roles with Johnson & Johnson Cordis from 1996-2008, including leader of the structural heart disease group in the United States; vice president of new business development in Europe and vice president of the Cordis cardiology division in Belgium; and general manager of Cordis France. Lemercier has more than 30 years of medical device experience, beginning with Baxter in France, and held several sales and marketing management positions within Baxter Europe and the United States. Lemercier holds a degree as a doctor in pharmacy from the Claude Bernard Lyon 1 University in Lyon, France.

Christine Z. McCauley has been corporate vice president, human resources, since 2012. McCauley has more than 30 years of experience working in all the functional disciplines of human resources. Prior to assuming her current role, she served as Edwards' vice president, human resources. Before joining the company in 1999, McCauley held a variety of human resources positions at Texas Instruments, Loral (Ford) Aerospace and Bally's Health and Tennis. She is a member of the board of directors at OCTANe and Baxter Credit Union. McCauley earned a dual bachelor's degree in business administration and organizational effectiveness at The College at Brockport State University of New York and a master's degree in human resource management from Chapman University.

John P. McGrath, Ph.D., has been corporate vice president, quality, since 2007. He has more than 30 years of medical device and combination product experience in quality, manufacturing and product development. Prior to joining Edwards, McGrath was vice president of quality at Cordis Corporation in Miami Lakes, Fla., where his quality assurance responsibilities included cardiovascular, endovascular and neurovascular businesses. Prior to that, he was director of quality at CR Bard's USCI and electrophysiology divisions. He received a bachelor's degree from Trinity College, Dublin, Ireland, a master's degree in total quality management from Sheffield Hallam University, United Kingdom, and a doctorate degree in management from California Coast University.

Joseph Nuzzolese joined Edwards as corporate vice president, global supply chain, in August 2016. Prior to joining the company, Nuzzolese was the vice president, supply chain, for Johnson & Johnson’s global surgery business, where he was responsible for leading worldwide operations for the Ethicon and Cardio and Specialty Surgery Businesses, which included Ethicon, Ethicon EndoSurgery, Biosurgery, Biosense Webster, Acclarent, Mentor, Advanced Sterilization Products and Sterilmed. Nuzzolese has more than 25 years of experience leading all facets of supply chain and held a number of senior leadership roles at Johnson & Johnson, including vice president of supply chain in the Office of Strategy & Execution, vice president of worldwide operations for Ethicon Endo-Surgery, Inc. and vice president of drug delivery for ALZA Corp. Nuzzolese was appointed to the Orange County United Way Board of Directors in July 2018. In November 2018, he joined the Albert Dorman Honors College Board of Visitors at the New Jersey Institute of Technology (his alma mater). Nuzzolese received his bachelor’s degree in electrical engineering from the New Jersey Institute of Technology.

Katie Szyman has been corporate vice president since 2015 and is currently responsible for the company’s global critical care and vascular business. Prior to joining Edwards, Szyman held a variety of roles with increasing levels of responsibility for more than 20 years at Medtronic. She served as president of Medtronic’s global diabetes business for five years, overseeing research, development, operations, and sales and marketing. She also served as senior vice president of corporate strategy and business development, VP and general manager of endovascular, and VP of finance for the vascular business. Szyman currently serves on the board of Endotronix. She previously served on the boards of Tornier, Inspire Medical Systems and the California Healthcare Institute (CHI). She graduated from the University of St. Thomas and earned her master’s degree in business administration from Harvard Business School.

Scott B. Ullem has been corporate vice president, chief financial officer since January 2014. Prior to joining Edwards, he was the chief financial officer of Bemis Company, a Fortune 500 packaging company focused on the consumer products, food and healthcare industries. Ullem also had leadership responsibility for one of Bemis' three business segments and the company's information technology function. Before joining Bemis, Ullem spent 17 years in global investment banking, serving as managing director at Goldman Sachs and later for Bank of America. He serves on the board of directors for Berry Global, Inc. and is a Henry Crown Fellow at the Aspen Institute. He is a passionate supporter of healthcare initiatives aimed at improving hospital quality and safety. Ullem received a bachelor's degree in political science from DePauw University and a master's degree in business administration from Harvard Business School.

Huimin Wang, M.D., is corporate vice president, Japan, Asia and Pacific. Prior to his current role, Wang was responsible for the company’s Japan and Intercontinental regions. Since joining the company – then Baxter International – in 1993, Wang has served in a number of roles, including senior manager of strategy development, director of product/therapy for Baxter’s renal division in Japan, president of medical systems and devices, responsible for both the cardiovascular and intravenous systems businesses in Japan, and representative director of Baxter Limited. Before joining Baxter, Wang was a senior associate with Booz, Allen & Hamilton in Chicago, vice president of Integrated Strategies, a consulting and venture management firm he co-founded, and an associate with McKinsey & Company. Prior to that, Wang was a resident and staff physician in anesthesiology at Keio University Hospital in Tokyo. In 2006, Wang was appointed as visiting associate professor for Keio University's department of anesthesiology. Wang received a doctor of medicine degree from Kagoshima University in Japan, and a master’s degree in business administration from the University of Chicago.

Aimee S. Weisner has been corporate vice president, general counsel, since 2011. Prior to joining the company, Weisner was the executive vice president, administration, and secretary at Advanced Medical Optics, Inc. (AMO), where she was responsible for legal, human resources, compliance and internal audit, and previously served as general counsel. Prior to that, Weisner served as vice president, assistant general counsel and assistant secretary at Allergan. She also practiced in the corporate and securities group at the law firm of O'Melveny & Myers LLP. Weisner currently serves as a board and audit committee member for Glaukos Corporation (NYSE: GKOS). She received a bachelor's degree in communications from California State University, Fullerton, and a juris doctor degree from Loyola Law School in Los Angeles.

Larry L. Wood has been corporate vice president, Transcatheter Aortic Valve Replacement, since 2007, and has been responsible for key company R&D, operations, marketing, commercial, clinical and regulatory initiatives in transcatheter valve replacement around the globe since the program was a development project. Under his leadership, the Edwards SAPIEN heart valve has won numerous awards, including the Prix Galien “Best Medical Technology Product” award and was named Popular Science’s “Best of What’s New” Grand Award winner in the Health category. Wood has more than 25 years of experience in the medical device industry at both Edwards and Baxter International, and is a frequently invited faculty member at key interventional cardiology and cardiothoracic surgery scientific congresses. Wood previously held key positions in manufacturing management, regulatory affairs, and strategic and clinical marketing, primarily in the company’s leading surgical heart valve franchise. Wood received his master’s degree in business administration from Pepperdine University.

Bernard J. Zovighian has been corporate vice president since January 2016 and is currently responsible for the company’s Transcatheter Mitral and Tricuspid Therapies (TMTT) business. He joined Edwards Lifesciences in January 2015 as vice president and general manager of the Surgical Heart Valve Therapy (HVT) business, served as corporate vice president of HVT in 2016-2017, and became corporate vice president of TMTT in 2018. Prior to joining Edwards, Zovighian held a variety of roles with increasing levels of responsibility at Johnson & Johnson (J&J) for nearly 20 years. He served as the worldwide president of Advanced Sterilization Products, a J&J company. He was also president of JJMP, J&J’s medical device businesses in Canada. Prior to leading JJMP, Zovighian was with Cordis, a J&J company at the time, for over a decade. Zovighian has extensive senior leadership experience in the medical technology industry in Europe and North America where he has led the development and adoption of disruptive technology that has elevated the standard of care. He received a master’s degree in biomedical engineering from University of Marseille and an executive MBA from Euromed Management, both in France.